Abstract: The present application relates to a novel benzoazepine compound, comprising a pharmaceutically acceptable salt thereof. The present application also provides a pharmaceutical composition comprising the compound and a pharmaceutically acceptable salt thereof. The present application relates to use of the compound and the composition in the prevention or treatment of diseases related to arginine vasopressin V1a receptor, arginine vasopressin V1b receptor, arginine vasopressin V2 receptor, sympathetic nervous system or renin-angiotensin-aldosterone system. The present application also provides a method for preventing and/or treating arginine vasopressin-related diseases.

Abstract: Disclosed are a pharmaceutical composition and method for relieving/eliminating morphine-induced analgesic tolerance. The pharmaceutical composition includes a therapeutically effective amount of a short peptide and morphine as active ingredients, and a pharmaceutically-acceptable carrier. The short peptide is a peptide consisting of an amino acid sequence shown in SEQ ID NO: 1 or a pharmaceutically-acceptable salt thereof. In the method, the short peptide and morphine are administered to a subject simultaneously; or the short peptide is injected to the subject followed by administration of the morphine; or a pharmaceutical composition including the short peptide and morphine is administered to the subject.